Title : Synergistic disruption of ERĪ±/HER2 crosstalk by endoxifen and lapatinib in breast cancer cells.

Pub. Date : 2017 Jan

PMID : 27942916






5 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 BACKGROUND: Despite decades of clinical success, tamoxifen therapy is complicated by inter-individual variability due to CYP450 polymorphism and resistance attributed to ERalpha/HER2 crosstalk. Tamoxifen erb-b2 receptor tyrosine kinase 2 Homo sapiens
2 CONCLUSION: This forward-looking study extends the success of tamoxifen by exploring the effectiveness of combining the next-generation tamoxifen derivative, endoxifen with an anti-HER2 agent to combat ERalpha/HER2 crosstalk, and at the same time provides a solution to the predicted pharmacokinetic antagonism between lapatinib and tamoxifen. Tamoxifen erb-b2 receptor tyrosine kinase 2 Homo sapiens
3 CONCLUSION: This forward-looking study extends the success of tamoxifen by exploring the effectiveness of combining the next-generation tamoxifen derivative, endoxifen with an anti-HER2 agent to combat ERalpha/HER2 crosstalk, and at the same time provides a solution to the predicted pharmacokinetic antagonism between lapatinib and tamoxifen. Tamoxifen erb-b2 receptor tyrosine kinase 2 Homo sapiens
4 CONCLUSION: This forward-looking study extends the success of tamoxifen by exploring the effectiveness of combining the next-generation tamoxifen derivative, endoxifen with an anti-HER2 agent to combat ERalpha/HER2 crosstalk, and at the same time provides a solution to the predicted pharmacokinetic antagonism between lapatinib and tamoxifen. Tamoxifen erb-b2 receptor tyrosine kinase 2 Homo sapiens
5 CONCLUSION: This forward-looking study extends the success of tamoxifen by exploring the effectiveness of combining the next-generation tamoxifen derivative, endoxifen with an anti-HER2 agent to combat ERalpha/HER2 crosstalk, and at the same time provides a solution to the predicted pharmacokinetic antagonism between lapatinib and tamoxifen. Tamoxifen erb-b2 receptor tyrosine kinase 2 Homo sapiens